Download PDF
Thromb Haemost 2002; 88(05): 756-762
DOI: 10.1055/s-0037-1613298
Review Article
Schattauer GmbH

The Role of the Factor X Activation Peptide: A Deletion Mutagenesis Approach[*]

Amy E. Rudolph
1   Departments of Pathology and Medicine, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
,
Michael P. Mullane   2
1   Departments of Pathology and Medicine, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
,
Rhonda Porche-Sorbet
1   Departments of Pathology and Medicine, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
,
Heather A. Daust   3
1   Departments of Pathology and Medicine, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
,
Joseph P. Miletich   4
1   Departments of Pathology and Medicine, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
› Author Affiliations
Further Information

Publication History

Received 19 June 2001

Accepted after resubmission 31 July 2002

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

To understand the role of the factor X (fX) activation peptide (AP), a deletion mutagenesis approach was employed. Two single-chain, variant enzymes were generated in which 41 residues were deleted from the AP: fXdes-137-183 and fXdes-137-183;N191A, which lacks a carbohydrate moiety at Asn191 due to an alanine substitution. Deletion of the fX AP did not impact fXa catalytic activity. Activation of the variant zymogens, however, was altered. Neither mutant enzyme was activated by the fX coagulant protein from Russell’s viper venom (RVV-X1). Activation by factor VIIa (fVIIa) and fVIIa in the presence of cofactor, lipidated tissue factor (TF), occurred at an accelerated rate for both variants as compared to wild-type fX (WTfX). Similar to fVII, the mutants auto-activated in a cofactor-independent manner, which was characterized by a lag period and accelerated dose-dependently by plasma fXa (kcat/Km, 0.046 ± 0.004 µM−1s−1). Both mutants were also found to be activated by fVIIa (0.31 ± 0.03 µM−1s−1), fIXa (0.30 ± 0.03 µM−1 s−1), and thrombin (0.00078 ± 0.00015 µM−1s−1). In all cases, the rate of activation was faster for fXdes-137-183;N191A as compared to fXdes-137-183. We propose that the fX AP and Asn191 carbohydrate serve primarily as negative autoregulation mechanisms to prevent spurious activation of fX and secondarily in cofactor dependence and activator specificity.

The abbreviations used are: TF, human tissue factor; AP, activation peptide; HEPES, (N-[2-Hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]); PEG, polyethylene glycol 8000; BSA, bovine serum albumin; Tris, (Tris[hydroxymethyl] aminomethane); EDTA, (Ethylenedinitrilo)-tetraacetic acid; SDSPAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; RVV-X, X activating protein from Russell’s viper venom; gla, γ-carboxylated glutamic acid; WTfX, wild type factor X; PC:PS, phosphatidylcholine:phosphatidylserine; fXa, fIXa, f Va, fVIIa, and fVIIIa, activated coagulation factor X, IX, V, VII, and VIII; ATIII, antithrombin; TFPI, tissue factor pathway inhibitor.

Keywords

Factor X - activation peptide - deletion

2 Present Address: Oncology of Wisconsin-Racine, Racine, WI 53406


3 Present Address: Pharmacia Corp., St. Louis, MO 63167


4 Present Address: Merck & Co., Inc., West Point, PA 19486


* This work was supported in part by grants from the National Institutes of Health Grant (NHLBI HL14147) and the Monsanto/Searle Company


 

  • References

  • 1 Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-102.
    CrossrefPubMedSearch in Google Scholar
  • 2 Jesty J, Spencer AK, Nemerson Y. The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X. J Biol Chem 1974; 249: 5614-22.
    PubMedSearch in Google Scholar
  • 3 Pfeiffer RA, Ott R, Gilgenkrantz S, Alexandre P. Deficiency of coagulation factors VII and X associated with deletion of a chromosome 13 (q34). Evidence from two cases with 46,XY,t(13;Y)(q11;q34). Hum Genet 1982; 62: 358-60.
    PubMedSearch in Google Scholar
  • 4 Nemerson Y, Bach R. Tissue factor revisited. Prog Hemostas Thromb 1982; 06: 237-61.
    PubMedSearch in Google Scholar
  • 5 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
    PubMedSearch in Google Scholar
  • 6 Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 915-56.
    CrossrefPubMedSearch in Google Scholar
  • 7 DiScipio RG, Hermodson MA, Davie EW. Activation of human factor X (Stuart factor) by a protease from Russell’s viper venom. Biochemistry 1977; 16: 5253-60.
    CrossrefPubMedSearch in Google Scholar
  • 8 Brandstetter H, Kuhne A, Bode W. et al. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem 1996; 271: 29988-92.
    CrossrefPubMedSearch in Google Scholar
  • 9 Padmanabhan K, Padmanabha KP, Tulinsky A. et al. Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol 1993; 232: 947-66.
    CrossrefPubMedSearch in Google Scholar
  • 10 Duffy EJ, Lollar P. Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191. J Biol Chem 1992; 267: 7821-7.
    CrossrefPubMedSearch in Google Scholar
  • 11 Lollar P, Parker CG, Kajenski PJ, Litwiller RD, Fass DN. Degradation of coagulation proteins by an enzyme from Malayan pit viper (Agkistrodon rhodostoma) venom. Biochemistry 1987; 26: 7627-36.
    CrossrefPubMedSearch in Google Scholar
  • 12 Iino M, Takeya H, Nishioka J, Nakagaki T, Tamura K, Suzuki K. The role of human factor X activation peptide in activation of factor X by factor IXa. J Biochem (Tokyo) 1994; 116: 335-40.
    CrossrefPubMedSearch in Google Scholar
  • 13 Baugh RJ, Krishnaswamy S. Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex. J Biol Chem 1996; 271: 16126-34.
    CrossrefPubMedSearch in Google Scholar
  • 14 Jackson CM, Hanahan DJ. Studies on bovine factor X II. Characterization of purified factor X. Observations on some alterations in zone electrophoresis and chromatographic behavior occurring during purification. Biochemistry 1968; 07: 4506-17.
    CrossrefPubMedSearch in Google Scholar
  • 15 Jackson CM. Characterization of two glycoprotein variants of bovine factor X and demonstration that the factor X zymogen contains two polypeptide chains. Biochemistry 1972; 11: 4873-81.
    CrossrefPubMedSearch in Google Scholar
  • 16 Fujikawa K, Thompson AR, Legaz ME, Davie EW. Biological properties of bovine factor X (Stuart Factor). Fed Proc Fed Amer Soc Exp Biol 1971; 30: 1075.
    PubMedSearch in Google Scholar
  • 17 Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor X. J Biol Chem 1993; 268: 3048-51.
    PubMedSearch in Google Scholar
  • 18 Inou K, Moria T. Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X. The role of the carbohydrate moieties in the activation of factor X. Eur J Biochem 1993; 218: 153-63.
    CrossrefPubMedSearch in Google Scholar
  • 19 Chavin SI, Weidner SM. Blood clotting factor IX. Loss of activity after cleavage of sialic acid residues. J Biol Chem 1984; 259: 3387-90.
    PubMedSearch in Google Scholar
  • 20 Bharadwaj D, Harris RJ, Kisiel W, Smith KJ. Enzymatic removal of sialic acid from human factor IX and factor X has no effect on their coagulant activity. J Biol Chem 1995; 270: 6537-42.
    CrossrefPubMedSearch in Google Scholar
  • 21 Rudolph AE, Porche-Sorbet R, Miletich JP. Substitution of asparagine for arginine 347 of recombinant factor Xa markedly reduces factor Va binding. Biochemistry 2000; 39: 2861-67.
    CrossrefPubMedSearch in Google Scholar
  • 22 Rudolph AE, Mullane MP, Porche-Sorbet RP. et al. Factor X St. Louis II. Identification of a glycine substitution at residue 7 and characterization of the recombinant protein. J Biol Chem 1996; 271: 28601-6.
    CrossrefPubMedSearch in Google Scholar
  • 23 Rudolph AE, Mullane MP, Porche-Sorbet RP, Miletich JP. Expression, purification, and characterization of recombinant human factor X. Protein Exp Purif 1997; 10: 373-8.
    CrossrefPubMedSearch in Google Scholar
  • 24 Cook BC, Rudolph AE, Kurumbail RG, Porche-Sorbet R, Miletich JP. Directed glycosylation of human coagulation factor X at residue 333. Insight into factor Va-dependent prothrombin catalysis. J Biol Chem 2000; 275: 38774-9.
    CrossrefPubMedSearch in Google Scholar
  • 25 Rudolph AE, Porche-Sorbet R, Miletich JP. Definition of a factor Va binding site in factor Xa. J Biol Chem 2001; 276: 5123-8.
    CrossrefPubMedSearch in Google Scholar
  • 26 Jiskoot W, Teerlink T, Beuvery EC, Crommelin DJ. Preparation of liposomes via detergent removal from mixed micelles by dilution. The effect of bilayer composition and process parameters on liposome characteristics. Pharm Weekbl Sci 1986; 08: 259-65.
    CrossrefPubMedSearch in Google Scholar
  • 27 Kisiel W, Hermodson MA, Davie EW. Factor X activating enzyme from Russell’s viper venom: isolation and characterization. Biochemistry 1976; 15: 4901-6.
    CrossrefPubMedSearch in Google Scholar
  • 28 Fass DN, Knutson GJ, Katzmann JA. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 1992; 59: 594-600.
    PubMedSearch in Google Scholar
  • 29 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
    CrossrefPubMedSearch in Google Scholar
  • 30 Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-67.
    CrossrefPubMedSearch in Google Scholar
  • 31 Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal. Biochem 1996; 237: 260-73.
    PubMedSearch in Google Scholar
  • 32 Myrmel KH, Lundblad RL, Mann KG. Characteristics of the association between prothrombin fragment 2 and alpha-thrombin. Biochemistry 1976; 15: 1767-73.
    CrossrefPubMedSearch in Google Scholar
  • 33 Luckow EA, Lyons DA, Ridgewa TM, Esmon CT, Laue TM. Interaction of clotting factor V heavy chain with prothrombin and prethrombin 1 and role of activated protein C in regulating this interaction: analysis by analytical ultracentrifugation. Biochemistry 1989; 28: 2348-54.
    CrossrefPubMedSearch in Google Scholar
  • 34 Esmon CT, Jackson CM. The conversion of prothrombin to thrombin. IV. The function of the fragment 2 region during activation in the presence of factor V. J Biol Chem 1974; 249: 7791-7.
    PubMedSearch in Google Scholar
  • 35 Furie BC, Furie B, Gottlieb AJ, Williams WJ. Activation of bovine factor X by the venom coagulant protein of Vipera russelli: complex formation of the activation fragments. Biochim Biophys Acta 1974; 365: 121-32.
    CrossrefPubMedSearch in Google Scholar
  • 36 Shah AM, Kisiel W, Foster DC, Nelsestuen GL. Manipulation of the membrane binding site of vitamin K-dependent proteins: enhanced biological function of human factor VII. Proc Nat. Acad Sci USA 1998; 95: 4229-34.
    CrossrefPubMedSearch in Google Scholar